In The News

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Dana-Farber/Boston Children’s Cancer and Blood Disorders Center was ranked highest for treating pediatric cancer in the latest rankings compiled by U.S. News & World Report.

     

Tags: ChildhoodCancer

  • Dr. Jennifer Ligibel comments on Dana-Farber offering complementary therapies to help patients.

  • Dr. Pasi Janne comments on the immunotherapy drug Keytruda for treating patients with non-small cell lung cancer.

Tags: LungCancer, Immunotherapy

  • In a step that could lead to a new diabetes treatment, Dana-Farber has joined several Boston-area hospitals and medical institutions to make personalized cell-based therapies and organize clinical trials.

     

Tags: BasicResearch, TargetedTherapy

  • Dr. David Reardon discusses the efficacy of two immunotherapy combinations for Glioblastoma.

    discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpufDr. D

Tags: BrainTumors

  • Dr. Nikhil Wagle led a study showing how the Internet can help recruit patients for breast cancer research.

     

Tags: BreastCancer

  • Dr. Eric Winer led a study showing women with early-stage breast cancer could benefit from taking an estrogen-suppressing drug for 10 years rather than the standard five.

Tags: BreastCancer

  • Dr. Stuart Orkin talks about plans to cut costs concerning gene therapies.

Tags: ChildhoodCancer

  • Dr. Geoffrey Oxnard is profiled along with one of his patients concerning targeted therapies to treat lung cancer.

Tags: LungCancer, TargetedTherapy

  • Dr. F. Stephen Hodi helped lead research showing the cancer drug Keytruda has helped about 40 percent of melanoma patients survive longer.

Tags: Melanoma

Showing 1-10 of 668 items